Latest Industry Insights

This article discusses an innovative biofabrication method that uses a single 3D hydrodynamic flow focusing chip to generate different hydrogel configurations with specific geometries for various biological applications.

Technology Networks recently had the pleasure of speaking with Mark Fidock, vice president for Diagnostic Development, Precision Medicine at AstraZeneca, to find out how the company is “rising to the challenge” of delivering precision medicines for chronic diseases.

Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.

In this interview with Bryan Kobel, CEO of TC Biopharm, we find out about gamma-delta T-cell therapy, including how it works, its applications and how TC Biopharm developed its pioneering gamma-delta treatment for acute myeloid leukemia.

In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.

Technology Networks learns about serum epitope repertoire analysis and some of the applications it could benefit, including cancer diagnostics and COVID-19 studies.

In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.

While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.

Technology Networks had the pleasure of interviewing Sunny Himansu M.B.B.S., D.SM – associate director, infectious diseases at Moderna – to discuss the biotech company's pipeline, how a collaboration with IAVI aims to make mRNA-based preventives and therapeutics globally accessible and the future of mRNA in medicine.

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).